Baiyong Li

This inventor holds 22 USPTO granted patents and 15 published patent applications and 8 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Akeso Biopharma, Inc., Ad Pharmaceutical Co., Inc., Akeso Pharmaceuticals, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Baiyong Li. Retrieved from https://idiyas.com/inventor/baiyong-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 15)

% Patents Active = 100.0

EPO Patents = 8 (Patent Applications = 47)

Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Zhongshan, CN (2019 - 2024)
Guangdong, CN (2019 - 2024)

Company Filing History:

13 out of 13

Akeso Biopharma, Inc.

patents

2 out of 2

Ad Pharmaceutical Co., Inc.

patents

2 out of 2

Akeso Pharmaceuticals, Inc.

patents

4. 2 out of 26

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

patents

5. 2 out of 2

Taizhou Hanzhong Biopharmaceutics, Inc.

patents

6. 1 out of 121

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

7. 1 out of 1

Cttq-Akeso (Shanghai) Biomed. Tech. Co., Ltd.

patent

8. 1 out of 1

Zeda Biopharmaceuticals, Inc.

patent

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Anti-CD47 Antibody

Anti-TIGIT Antibody

Anti-IL-1β Antibody

Bifunctional Antibody

Pharmaceutical Composition

Therapeutic Combination

Nucleic Acid Encoding

Monoclonal Antibody

Anti-PD-1 Antibody

PDL-1 Antibody

Anti-CTLA4 Antibody

Anti-VEGFA Antibody

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703743 - ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF (2026-08-11),

2. 12698327 - ANTI-TIGIT ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF (2026-08-04),

3. 12679887 - ANTI-INTERLEUKIN-17A ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF (2026-07-14),

4. 12595300 - ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF (2026-04-07),

5. 12479919 - ANTI-CTLA4 AND ANTI-PD-1 BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF (2025-11-25),

6. 12447208 - Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses (2025-10-21),

7. 12390458 - Therapeutic combination of quinoline derivative and antibody (2025-08-19),

8. 12286473 - Anti-IL-1β antibody and pharmaceutical composition thereof and use of same (2025-04-29),

9. 12195527 - Anti-PD-1/VEGFA bifunctional antibody, pharmaceutical composition thereof (2025-01-14),

10. 12076398 - Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof (2024-09-03),

11. 11976115 - Antibody binding to human IL-1β, preparation method therefor and use thereof (2024-05-07),

12. 11680095 - Monoclonal antibody against nerve growth factor, and encoding gene and use thereof (2023-06-20),

13. 11578128 - Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof (2023-02-14),

14. 11479608 - Anti-CTLA4 antibodies (2022-10-25),

15. 11402383 - Nucleic acid encoding PCSK9 antibody (2022-08-02),

Title: The Innovative Contributions of Baiyong Li

Introduction

Baiyong Li is a prominent inventor based in Guangdong, China. He has made significant contributions to the fields of tumor therapy and molecular immunology. With a total of 22 patents, his work has had a substantial impact on medical research and treatment options.

Latest Patents

One of his latest patents is the development of an anti-CTLA4 monoclonal antibody or its antigen binding fragments, along with pharmaceutical compositions and uses. This invention aims to block the binding of CTLA4 to B7, thereby relieving immunosuppression and activating T lymphocytes. Another notable patent involves a therapeutic combination of a quinoline derivative and an antibody, which includes an immune checkpoint inhibitor and a tyrosine kinase inhibitor. This combination has shown promising activity against lung and liver tumors.

Career Highlights

Baiyong Li has worked with several notable companies in the pharmaceutical industry, including Akeso Biopharma, Inc. and Ad Pharmaceutical Co., Inc. His expertise in immunology and tumor therapy has positioned him as a key figure in the development of innovative treatments.

Collaborations

Throughout his career, Baiyong Li has collaborated with esteemed colleagues such as Yu Xia and Zhongmin Maxwell Wang. These partnerships have further enhanced his research and contributions to the field.

Conclusion

Baiyong Li's innovative work in the realm of tumor therapy and molecular immunology continues to pave the way for advancements in medical treatments. His numerous patents reflect his dedication to improving healthcare outcomes.

Profile summary based on public USPTO records.